中国实用外科杂志

中国实用外科杂志

• 讲座 • 上一篇    下一篇

肝内胆管癌转化治疗

赵海涛，杨    旭   

  1. 北京协和医院肝脏外科，北京100630
  • 出版日期:2020-06-01 发布日期:2020-06-24

  • Online:2020-06-01 Published:2020-06-24

摘要： 肝内胆管癌（ICC）可切除率低，进展期ICC的治疗有效率不高，预后很差。转化治疗在多种晚期肿瘤中有一定的疗效，是目前晚期肿瘤治疗的研究热点。随着对ICC基因组的深入了解和新的治疗药物的开发及组合，基于系统化疗的联合治疗策略，精准靶向治疗，免疫检查点抑制剂等显示出较好的疗效，使得部分进展期ICC病人能降期转化手术，获得长期生存。

关键词: 肝内胆管癌, 转化治疗, 系统化疗, 靶向治疗, 免疫检查点抑制剂

Abstract: Conversion therapy of advanced intrahepatic cholangiocarcinoma        ZHAO Hai-tao, YANG Xu. Department of Liver Surgery，Peking Union Medical College Hospital，Beijing 100630，China
Corresponding author： ZHAO Hai-tao, E-mail：zhaoht@
pumch.cn
Abstract    Intrahepatic cholangiocarcinoma (ICC) has a low resectable rate. The effect of treatment and the prognosis are poor in advanced ICC. Conversion therapy shows a certain effect in the advanced tumors. With the understanding of the ICC genome and the development of new therapeutic drugs, combined strategies based on systemic chemotherapy, biomarker-driven targeted therapy and immune checkpoint inhibitors have shown promising efficacy. As a result, some advanced ICC patients have gotten experienced downstaging and undergone conversion therapy to achieve long-term survival.

Key words: intrahepatic cholangiocarcinoma, conversion therapy, systemic chemotherapy, targeted therapy, immune checkpoint inhibitors